After a multi-year run, sentiment around Eli Lilly (NYSE: LLY ) and the broader sector has deteriorated. This has resulted in steep underperformance relative to the market, driven by the market waiting for more clarityI am currently studying economics and accounting at UCSB, and interning at a UBS wealth management office. I am seeking a career in equity research, and I became passionate about equities through managing a stock portfolio of companies that I track closely.Analyst’s Disclosure:I/we have a bene ...

Group 1 - Investors are showing a bullish stance on Eli Lilly (NYSE: LLY), with significant options trades indicating potential insider knowledge of upcoming events [1][2] - The overall sentiment among large investors is split, with 34% bullish and 34% bearish, highlighting mixed expectations [2] - Notable options activity includes 15 call options totaling $1,103,597 and 8 put options totaling $646,055, suggesting a cautious approach among traders [2] Group 2 - Whales have targeted a price range for Eli Lilly between $640.0 and $850.0 over the last three months, indicating a focused investment strategy [3] - The mean open interest for Eli Lilly options trades is 754.85, with a total volume of 802.00, reflecting active trading interest [4] Group 3 - Eli Lilly's key products span various therapeutic areas, including neuroscience, cardiometabolic, cancer, and immunology, with notable drugs like Verzenio and Mounjaro [11] - Recent analyst opinions show a range of price targets, with an average target of $940.0, while one analyst lowered their rating to Hold with a target of $830, and another maintained an Overweight rating with a target of $1050 [12][13] Group 4 - The current stock price of Eli Lilly is $718.34, down 0.86%, with upcoming earnings expected in 30 days [15]

HOUSTON, TEXAS - SEPTEMBER 23: Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. (Raquel Natalicchio/Houston Chronicle via Getty Images)Houston Chronicle via Getty ImagesEli Lilly stock (NYSE: LLY) should be on your radar. Here’s why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly. Over the past 10 years, the stock has attracted buying interest at this level 5 time ...

Core Insights - The article discusses the performance of value stocks, particularly those that pay dividends, highlighting their historical outperformance compared to growth stocks [2][4]. Value Stocks Performance - Value stocks, defined by low price-to-book ratios, have outperformed growth stocks by an average of 2.5% annually since 1926 [2]. - The trend of value stocks outperforming growth stocks was disrupted during the global financial crisis from 2007 to 2020, but value stocks regained some traction in 2020 before losing ground again in late 2022 [2]. Investment Strategy - Joseph H. Davis from Vanguard emphasizes the importance of broad diversification and focusing on undervalued stocks to mitigate risks associated with market transformations, such as those driven by artificial intelligence [3]. Methodology for Stock Selection - The article utilizes Insider Monkey's Q2 2025 database to identify dividend stocks with forward P/E ratios below 25 as of September 26, ranking them based on hedge fund interest [6]. Company Highlights - **Eli Lilly and Company (NYSE: LLY)** - Forward P/E as of September 26: 23.70 - Major revenue drivers include Mounjaro, Zepbound, and Verzenio, which contributed to 65% of Q2 revenue of $15.6 billion, with growth rates between 12% and 172% [9]. - R&D expenses increased by 23% year-over-year to $3.3 billion, representing over 21% of revenue [10]. - The company has raised dividends for 11 consecutive years, currently offering $1.50 per share with a yield of 0.83% [11]. - **Abbott Laboratories (NYSE: ABT)** - Forward P/E as of September 26: 23.42 - Declared a quarterly dividend of $0.59 per share, maintaining a 53-year streak of dividend increases, with a yield of 1.77% [13]. - The FreeStyle Libre glucose monitoring system has become a significant growth driver despite a decline in COVID-19 test sales [14]. - **Illinois Tool Works Inc. (NYSE: ITW)** - Forward P/E as of September 26: 22.47 - Focuses on efficiency and customer-driven innovation, with a strategy that emphasizes operational improvements and disciplined portfolio management [15][16]. - Announced a 7.3% increase in its quarterly dividend to $1.61 per share, extending its dividend growth streak to 53 years, with a yield of 2.47% [17].

The blockbuster medications could open a new frontier for the pharma giants. ...

ab 23 September 2025 Global Research Global Pharmaceuticals Framing Global GLP-1 forecasts to 2030 UBS forecast $130bn GLP-1 sales in 2030 Over the last 12 months, the outlook for the GLP-1 market for both obesity and type-2 diabetes (T2D) has weakened driven by the disruption from compounded product in the US market and from weaker than expected data from next generation assets (CagriSema and orforglipron). This has seen UBS 2030 global forecasts cut from > $150bn to $130bn, which assumes c.$80bn sales for ...

Core Insights - Eli Lilly has shown strong performance in the GLP-1 market, with significant commercial success from its products, particularly tirzepatide [1][10] - The company is on the verge of launching an oral GLP-1 medication, orforglipron, which has demonstrated superior efficacy in clinical trials compared to existing treatments [7][8] - Financial results indicate robust growth, with a 38% year-over-year revenue increase in Q2, reaching $15.6 billion, and a 61% rise in adjusted net earnings per share to $6.31 [10] Group 1: Product Development - Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, is generating billions in sales but is administered via injection, which has drawbacks compared to oral medications [3][4] - The company is developing orforglipron, which has shown a 1.9% average blood-sugar reduction and 8.2% weight loss in trials, outperforming Novo Nordisk's Rybelsus [7][8] - If orforglipron receives regulatory approval by year-end, it could significantly boost Eli Lilly's stock value [8][9] Group 2: Financial Performance - Eli Lilly's revenue and earnings growth outpace industry averages, with a forward P/E ratio of 24.7 compared to the healthcare industry's 16.5 [10][11] - Analysts project orforglipron could generate $12.7 billion in revenue by 2030, while tirzepatide is expected to reach nearly $62 billion in revenue by the same year [12][13] - The company has additional products in the pipeline, such as Kisunla for Alzheimer's and Ebglyss for eczema, which could also contribute to future growth [14] Group 3: Market Outlook - Eli Lilly's strong clinical data and market position suggest continued growth in the GLP-1 sector, with expectations for market-beating returns over the next five years [15]

礼来宣布因"战略业务原因"终止一项2b期肥胖试验，该研究在尚未招募任何参与者前即被叫停。该试验原计划评估礼来以19亿美元收 购Versanis获得的资产bimagrumab，既作为单一疗法，也与其主力GLP-1/GIP药物替尔泊肽联合使用。 整理 | GLP1减重宝典内容团队 公司在今年3月提交了试验申请，计划招募180名肥胖或超重并伴有2型糖尿病的成年人。bimagrumab是一种抗体，通过结合激活素II 型A和B受体来阻断激活素和肌生成抑制素信号通路。研究设计了九个分组，分别测试bimagrumab单用或与替尔泊肽联合，后者正是 Mounjaro和Zepbound的活性成分。 据彭博社首次报道，该试验已被取消。早在6月，ClinicalTrials.gov上的试验状态就从"尚未招募"变更为"进行中但未招募"，引发外界 关注。 本周，该试验状态再次更新为"撤回"。礼来表示，此举是基于业务层面的考虑，公司"会常规性地评估研发管线，以最大化每一款产品 的潜力"。 礼来同时强调，bimagrumab仍在进行中的另一项2期试验中被研究，该试验评估其与替尔泊肽单独或联合在肥胖人群中的疗效。该研 究结果预计将在2026 ...

Market Overview - Wall Street is on track to end the week higher, with the Dow up approximately 360 points, S&P 500 up about 0.6%, and NASDAQ up about 0.4% [2][3] - The Dow is up 0.8% for the day, while the NASDAQ is down about 0.67% for the week, marking the worst performance since August 1st [3][4] - The 10-year Treasury yield has increased by one basis point, indicating a trend of rising yields since Wednesday [5] Inflation and Federal Reserve Insights - The core Personal Consumption Expenditures (PCE) index for August is reported at 2.9%, consistent with July's figures, suggesting inflation is stable but not accelerating [11][12] - Federal Reserve officials express concerns about persistent inflation, with some suggesting that productivity gains from AI could mitigate inflationary pressures [13][14] - The next jobs report is anticipated to be crucial for the Fed's decision-making regarding interest rates, especially if it indicates a soft job market [14][16] Tariff Implications - President Trump's new tariff threats, including a 50% duty on certain pharmaceuticals and furniture, are causing concern in the affected industries, particularly in the furniture sector [17][18] - Companies like Wayfair and RH are adapting by diversifying their supply chains away from China, while pharmaceutical companies with U.S. manufacturing facilities are less affected by the tariffs [19][20] - The impact of these tariffs on inflation and economic growth is expected to vary by industry, with some sectors facing more significant challenges than others [22][23] Digital Asset Treasuries - Over 180 public companies have added Bitcoin to their balance sheets, indicating a growing trend in digital asset treasuries [74] - Breer Holdings is rebranding as Soulmate, focusing on a Solana-based digital asset treasury, highlighting the shift towards blockchain technologies that can handle high transaction volumes [75][87] - The emergence of digital asset treasuries is seen as a response to previous regulatory challenges and market inefficiencies, with a focus on building actual infrastructure to support these assets [91][92] Weight Loss Drug Market - The GLP-1 weight loss drug market is projected to potentially reach $100 billion annually within the next decade, driven by innovations and expanded indications beyond obesity [106][108] - Current injectable GLP-1 drugs show weight loss efficacy between 12% to 20%, with oral formulations expected to be slightly less effective [110][111] - Eli Lilly and Novo Nordisk dominate the market, but Amgen is also making strides with late-stage trials for its weight loss drug [105][116]

Hours after President Donald Trump imposed 100% tariffs on pharmaceuticals with exemptions for companies building manufacturing plants in the U.S., Eli Lilly (NYSE:LLY) and Amgen (NASDAQ:AMGN) announced their latest investments in their home country. Lilly announced the opening of its ...